Future studies should integrate SIG with molecular subtypes (e.g., MSI/CIN status), immune microenvironment features (e.g., CD8+ T-cell infiltration), and gut microbiome biomarkers to construct multidimensional prognostic models, ultimately optimizing individualized therapeutic strategies. This evidence concerns the gene CD8A and cervical squamous intraepithelial neoplasia.